Exagen Inc. (XGN)
NASDAQ: XGN · Real-Time Price · USD
9.20
+0.21 (2.34%)
At close: Aug 8, 2025, 4:00 PM
9.31
+0.11 (1.20%)
After-hours: Aug 8, 2025, 7:54 PM EDT

Company Description

Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States.

The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).

Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms.

The company offers AVISE Lupus platform, a cornerstone of the SLE assessment that begins by quantifying the level of CB-CAPs biomarkers (EC4d and BC4d) in the patient’s blood; and AVISE APS that aids in the diagnosis and management of APS.

In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE Anti-Histone, a test for autoantibodies to histone proteins; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP, a biomarker-driven RA prognostic test.

Further, the company offers AVISE SLE Monitor, a blood test that employs CB-CAPs technology; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine.

It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop T-Cell biomarkers.

The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019.

Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

Exagen Inc.
Exagen logo
CountryUnited States
Founded2002
IPO DateSep 19, 2019
IndustryDiagnostics & Research
SectorHealthcare
Employees215
CEOJohn Aballi

Contact Details

Address:
1261 Liberty Way, Suite C
Vista, California 92081
United States
Phone760 560 1501
Websiteexagen.com

Stock Details

Ticker SymbolXGN
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$14.00
CIK Code0001274737
CUSIP Number30068X103
ISIN NumberUS30068X1037
SIC Code8071

Key Executives

NamePosition
John AballiChief Executive Officer, President and Director
Dr. Tina S. Nova Ph.D.Executive Chairman of the Board of Directors
Jeffrey G. BlackChief Financial Officer and Corporate Secretary
Dr. Michael MahlerChief Scientific Officer
Ryan DouglasInvestors Relations Officer
Dr. Michael I. Nerenberg M.D.Chief Medical Officer

Latest SEC Filings

DateTypeTitle
Jul 29, 202510-QQuarterly Report
Jul 29, 20258-KCurrent Report
Jul 17, 20258-KCurrent Report
Jul 2, 2025EFFECTNotice of Effectiveness
Jun 30, 2025UPLOADFiling
Jun 20, 2025S-3Registration statement under Securities Act of 1933
Jun 11, 20258-KCurrent Report
May 20, 2025S-8Securities to be offered to employees in employee benefit plans
May 12, 2025SCHEDULE 13G/AFiling
May 9, 20258-KCurrent Report